References
●Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation: J.H. Hanke, et al.; J. Biol. Chem. 271, 695 (1996)|●Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis: J.S. Nam, et al.; Clin. Cancer Res. 8, 2430 (2002)|●Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolopyrimidine (PP2): F. Carlomagno, et al.; J. Clin. Endocrinol. Metab. 88, 1897 (2003)|●The specificities of protein kinase inhibitors: an update: J. Bain, et al.; Biochem. J. 371, 199 (2003)|●Apoptotic effect of PP2 a Src tyrosine kinase inhibitor, in murine B cell leukemia: M. Lee, et al.; J. Cell Biochem. 93, 629 (2004)|●The selectivity of protein kinase inhibitors: a further update: J. Bain, et al.; Biochem. J. 408, 297 (2007)|●The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors: H. Ungefroren, et al.; Curr. Cancer Drug Targets 11, 524 (2011)|●Suppression of autophagy sensitizes multidrug resistant cells towards Src tyrosine kinase specific inhibitor PP2: J.H. Ahn & M. Lee; Cancer Lett. (Epub ahead of print) (2011)USBio References
No references available
TDS
NCBI
UniProt
Tech Support
Customer Service
